Gene transfer strategies to reduce levels of mutant huntingtin (mHtt) mRNA and protein by targeting human Htt have shown therapeutic promise in vivo. Previously, we have reported that a specific, adenoassociated viral vector (rAAV)-delivered short-hairpin RNA (siHUNT-2) targeting human Htt mRNA unexpectedly decreased levels of striatalspecific transcripts in both wild-type and R6/1 transgenic HD mice. The goal of this study was to determine whether the siHUNT-2-mediated effect was due to adverse effects of RNA interference (RNAi) expression in the brain. To this end, we designed two catalytically active hammerhead ribozymes directed against the same region of human Htt mRNA targeted by siHUNT-2 and delivered them to wild-type and R6/1 transgenic HD mice. After 10 weeks of continuous expression, these ribozymes, like siHUNT-2, negatively impacted the expression of a subset of genes in the striatum. This effect was independent of rAAV transduction and specific to the targeting of a unique sequence in human Htt mRNA. After consideration of the known potential RNAi-specific toxic mechanisms, only cleavage of an unintended RNA target can account for the data reported herein. Thus, long-term rAAV-mediated RNAi in the brain does not, in and of itself, negatively affect striatal gene expression. These findings have important implications in the development of therapeutic RNAi for the treatment of neurological disease.
Introduction
The underlying cause of Huntington's disease (HD) is the inheritance of a copy of the gene encoding Htt with an expanded polyglutamine-encoding CAG repeat located within the 5′ end of the coding region (HDCRG, 1993) . The mutant huntingtin protein (mHtt) is expressed during development through adulthood, causes neuronal dysfunction, and ultimately cell death of neurons in the striatum and neuropathology is present to a varying extent in other regions of the brain (Schilling et al., 1995; Sharp et al., 1995) . The development of motor, cognitive and psychiatric symptoms of the disease, like neuronal cell loss, is slow and progressive, generally affecting HD patients in mid-adulthood. The disease is inevitably fatal after a period of worsening symptoms. Although, there are a number of pharmacological treatments that have shown promise at reducing symptoms and cellular pathology and increasing survival in transgenic HD mice (Chen et al., 2000; Dedeoglu et al., 2002; Ferrante et al., 2002 Ferrante et al., , 2000 Ferrante et al., , 2003 Ferrante et al., , 2004 Ona et al., 1999; Van Raamsdonk et al., 2005) , treatment of HD patients is very limited.
The precise function of normal Htt and the abnormal function acquired by the mutant form of the protein are not fully understood (Cattaneo et al., 2005; Li and Li, 2004) . It is clear that continued expression of mHtt is required for disease progression as conditional knock-out mice do not display HDlike motor symptoms after mHtt expression is blocked (Yamamoto et al., 2000) . This observation demonstrated that lowering mHtt levels would likely be beneficial for the treatment of HD. Several groups, including ours, have now shown that it is possible to reduce the levels of mHtt mRNA post-transcriptionaly using a variety of strategies that include antisense oligonucleotides, DNA enzymes, ribozymes and siRNAs in culture cells (Boado et al., 2000; Chen et al., 2005; Hasholt et al., 2003; Nellemann et al., 2000; Omi et al., 2005; Park et al., 2004; Yen et al., 1999) .
